Status:
COMPLETED
Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET
Lead Sponsor:
Centre Oscar Lambret
Collaborating Sponsors:
Ministry of Health, France
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE4
Brief Summary
18F-FDG PET, a whole-body imaging technology based on glucose metabolism, can effectively detect subclinical and clinical therapeutic responses at stages that are earlier than those detected by conven...
Detailed Description
Further study details as provided by Centre Oscar Lambret
Eligibility Criteria
Inclusion
- Age \> 18
- Breast cancer treated by neo-adjuvant chemotherapy (T\>2cm)
- Measurable lesions ,assessed clinically and by ultrasound
- Delay minimum between biopsy and PET: 15 days
- PS-WHO: 0
Exclusion
- T\<2cm
- Inflammatory breast cancer (T4d)
- Diabetic patients unbalanced (glycemia\>1.40)
- Pregnant or lactating women
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT00904410
Start Date
May 1 2005
End Date
January 1 2008
Last Update
July 23 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Oscar Lambret
Lille, France, 59020